We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Circassia Group Plc | LSE:CIR | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 34.00 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 33.10 | 34.90 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 34.00 | GBX |
Circassia (CIR) Share Charts1 Year Circassia Chart |
|
1 Month Circassia Chart |
Intraday Circassia Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 02/1/2023 | 06:10 | Circassia Pharma - Focussed on respiratory disease | 1,127 |
| 28/1/2022 | 14:25 | Circassia Pharma PLC | 1,227 |
| 27/1/2020 | 16:20 | money wanted | - |
| 13/12/2019 | 08:24 | Capricorn Resouces PLC - 50% premium in half a day | 814 |
| 10/2/2005 | 15:35 | 100 % on no time | 12 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 14/9/2022 06:17 by masurenguy Positive set of interim results with net cash position at the end of August of £17.6mINTERIM RESULTS FOR THE SIX MONTHSED 30 JUNE 2022 Oxford, UK - 14 September 2022: NIOX Group plc announces its unaudited interim results for the six months ended 30 June 2022 ("H1 2022"). Financial highlights -- Underlying NIOX(R) revenue growth of 11% t o £15.5 million (excluding the effect of a one-off revenue item of £0.6 million recognised in H1 2021) -- The Group generated an adjusted EBITDA profit of £3.2 million (H1 2021: £0.3 million loss), reflecting improved margins and a substantial reduction in the cost base -- Strong balance sheet with no debt and cash of £13.8 million as of 30 June 2022 (30 June 2021: £11.3 million, 31 December 2021: £12.6 million) Operational highlights -- FDA approval for Beyond Air's LungFit(R) PH device received on 28 June 2022, initiating total milestone payments of $10.5 million over the next three years, with up to a further $6 million in royalty payments thereafter -- Ongoing transition to distributor-led business model with new arrangements in the USA and China expected to drive scalable revenue growth Post period end -- Initial payment of $2.5 million received from Beyond Air on 24 August 2022 -- Net cash at 31 August 2022 increased to £17.6 million -- The Company received approval from shareholders on 1 September 2022 to change its name from Circassia Group plc to NIOX Group plc The Company will shortly be proposing a capital reduction scheme to shareholders for approval in order to provide flexibility to enable the Board to return surplus cash to shareholders, via dividends and/or share buybacks, if considered appropriate in the future Ian Johnson, NIOX's Executive Chairman, said: "The Group has performed well in the first half of the year with good underlying growth in revenue and profits despite Covid-19 lockdowns persisting in China and the ongoing effects of Covid-19 on testing volumes in Japan. Cash generation remained strong with net cash at the half year of £13.8 million, up from £12.6 million at the end of 2021. Future revenue growth is likely to be driven by success in raising the awareness of the benefits of FeNO testing amongst clinicians, patients and drug developers, the continued expansion of our worldwide network of distributors and investing in the installed base of devices. The NIOX Group is now in a strong financial position to deploy its cash resources to invest in these areas and also to develop next generation devices, including a home-use device. The second half has started well with revenues for July and August taken together up 25% on the same period in 2021. Margins remain strong and costs are continuing at a much-reduced level. The Board remains confident of achieving management expectations for the full year, which were significantly upgraded in July." |
Posted at 12/5/2022 07:33 by drdre I have been watching CIR a while and impressed by recent newsflow. Whats the target addressable market they are in? |
Posted at 22/3/2022 07:23 by saadia110 Amazing results today, let's see the price action today. |
Posted at 10/3/2022 14:38 by thedudie Price being driven back up today - Recent trading statement said results are on 22 March. |
Posted at 10/2/2022 16:28 by masurenguy Took an opening position in CIR earlier today. |
Posted at 25/1/2022 19:41 by p1nkfish What a lovely bit of closing action. £8M+ at what appears just over the ask price.Something afoot? 41x average volume approx. |
Posted at 25/1/2022 16:52 by ayl30 Big trades and jump in price near the close, interesting! |
Posted at 13/1/2022 11:29 by apad CIR is commented on in this morning's SCVR.apad |
Posted at 12/1/2022 14:47 by masurenguy Re post #1057 - CIR was tipped this morning. |
Posted at 21/4/2021 14:29 by 1pencil On the topic of why would Astra Zeneca dispose of their holding. My reading of the situation is it formed part of the original partnership agreement back in 2017 (see below excerpt).Therefore it seems reasonable to assume AZ will at some point unwind this position now the partnership has ended. "Under the terms of the agreement, AstraZeneca will receive $50 million in Ordinary Shares in Circassia, calculated by reference to the lower of the weighted average share price of Circassia over the period 20 days (i) prior to signing or (ii) prior to closing (subject to a maximum number of shares). Circassia will also pay $100 million at the earlier of approval of Duaklir in the US or 30 June 2019. Should Circassia decide to exercise the option to sub-license the commercial rights to Tudorza in the US, Circassia will pay up to a further $80 million." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
